在接受过导管大动脉置换的患者中,脂蛋白和长期预后之间的关联
Xiangming Hu1, Can Wang1, Dejing Feng1
1Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Drs Hu, Wang, Feng, Li, Chen, Niu, Zhou, Zhang, Ye, Wang, and Wu).
Journal of clinical lipidology
|April 1, 2025
概括
升高的脂蛋白a (Lp[a]) 水平预测了严重的大动脉狭窄症的跨导管大动脉置换 (TAVR) 后的更糟糕的结果和生物假体退化.
科学领域:
- 心脏病学 心脏病学
- 生物医学科学 生物医学科学
- 临床研究 临床研究
背景情况:
- 脂蛋白 (Lp) 是一种已知的大动脉狭窄症 (AS) 的风险因素.
- 在接受过导管大动脉置换 (TAVR) 治疗严重AS的患者中,Lp[a]的预后价值尚未得到充分确立.
研究的目的:
- 评估基线Lp[a]水平与TAVR后的长期临床结果之间的关联.
- 调查Lp[a]对TAVR后生物假体退化的影响.
主要方法:
- 研究了一组601名患有严重AS的患者,接受TAVR治疗.
- 测量了手术前的Lp[a]水平,并根据Lp[a]度对患者进行了分层.
- 结果包括通过心声学评估的全因死亡率和结构退行 (SVD),使用Cox和竞争风险模型进行分析.
主要成果:
- 经过3.9年的中位数随访后,升高的Lp[a] (≥30 mg/dL) 独立预测了较高的全因死亡率 (HR 1.81) 和心血管死亡率 (HR 2.02).
- 更高的Lp[a]水平也与可能的SVD风险增加有显著的关联 (亚分布HR 3.40).
- 使用50mg/dL值的敏感性分析证实了这些发现.
结论:
- 升高的基线Lp[a]是不良临床结果的显著预测指标,包括死亡率和结构退行,在TAVR后严重AS患者.
- 这些发现突显了Lp[a]作为AS管理中的治疗点的潜在作用.
- 建议进行进一步的研究以验证这些结果并探索临床影响.
更多相关视频
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
5.2K
04:30Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
Published on: February 4, 2021
2.5K
相关概念视频
01:25Aortic Regurgitation III: Medical Management
598
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
598
01:26Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741